BACLOSIGN 25 Tablet is a high-strength skeletal muscle relaxant containing Baclofen 25 mg. It is primarily indicated for the treatment of severe spasticity associated with chronic neurological disorders such as multiple sclerosis, cerebral palsy, spinal cord injury, and post-stroke complications. By acting on GABA-B receptors in the spinal cord, BACLOSIGN 25 reduces abnormal muscle tone, relieves spasms, and enhances mobility. Manufactured under WHO-GMP-certified conditions, it is ideal for patients who require higher therapeutic dosing for sustained spasticity control.

This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.

BACLOSIGN 25 Tablet is an oral muscle relaxant formulation that contains Baclofen 25 mg, a potent GABA-B receptor agonist widely used in the management of moderate to severe muscle spasticity. This higher-dose version is intended for patients who do not achieve adequate symptom relief with lower doses such as 10 mg or 20 mg. BACLOSIGN 25 offers powerful antispastic effects and is particularly beneficial for individuals with advanced neurological impairments resulting in debilitating muscle stiffness and spasms. Its therapeutic effectiveness lies in its ability to reduce involuntary muscle contractions and improve overall motor function in conditions characterized by upper motor neuron lesions.

Baclofen, the active ingredient in BACLOSIGN 25, is structurally related to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It works by binding to GABA-B receptors in the brain and spinal cord, which leads to suppression of abnormal nerve transmission that causes muscle hyperactivity. This reduction in excitatory synaptic transmission allows for the relaxation of overactive muscles, improved limb control, and decreased pain associated with spasticity. BACLOSIGN 25 is commonly used in diseases such as multiple sclerosis, cerebral palsy, traumatic spinal cord lesions, stroke recovery, and brain injury, where muscle tone disruption interferes with mobility and quality of life.

The pharmacological action of Baclofen begins within a few hours of oral administration. BACLOSIGN 25 is rapidly absorbed through the gastrointestinal tract, and peak plasma concentrations are typically reached in two to three hours. The bioavailability ranges between 70% to 85%, and the drug readily crosses the blood-brain barrier to exert its central effects. Its elimination is primarily renal, with a plasma half-life of approximately 3 to 4 hours. For this reason, BACLOSIGN 25 is generally administered in divided doses two to three times per day to maintain consistent symptom control throughout the day.

Patients requiring BACLOSIGN 25 usually have been stabilized on lower doses of Baclofen before progressing to higher strengths. It is not recommended as an initial dose due to the potential for adverse effects such as sedation, dizziness, and muscle weakness. The transition to 25 mg tablets is made gradually under medical supervision, once the patient demonstrates tolerance to lower strengths like 10 mg or 20 mg. A typical maintenance regimen may include BACLOSIGN 25 taken two or three times daily, depending on the patient’s spasticity severity, therapeutic response, and renal function.

BACLOSIGN 25 is highly effective in providing symptomatic relief in individuals with chronic and disabling spasticity. In patients with multiple sclerosis, it alleviates painful muscle cramps, enhances ambulation, and improves participation in physical rehabilitation. In cases of spinal cord injury, BACLOSIGN 25 facilitates better limb positioning, reduces involuntary spasms, and aids in caregiving and hygiene activities. Stroke survivors often benefit from reduced flexor tone in limbs, allowing for greater independence in activities of daily living. Patients with cerebral palsy and brain injury also exhibit improved posture, joint mobility, and muscle coordination with Baclofen therapy.